BACOD regimen
WikiDoc Resources for BACOD regimen |
Articles |
---|
Most recent articles on BACOD regimen Most cited articles on BACOD regimen |
Media |
Powerpoint slides on BACOD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on BACOD regimen at Clinical Trials.gov Trial results on BACOD regimen Clinical Trials on BACOD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on BACOD regimen NICE Guidance on BACOD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on BACOD regimen Discussion groups on BACOD regimen Patient Handouts on BACOD regimen Directions to Hospitals Treating BACOD regimen Risk calculators and risk factors for BACOD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for BACOD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: BACOD; BLEO/CTX/DM/DOX/VCR; Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Vincristine regimen
Overview
BACOD regimen refers to an immunochemotherapy regimen consisting of bleomycin, doxorubicin, cyclophosphamide ,vincristine ,dexamethasone used to treat relapsed and refractory diffuse large B cell lymphoma .[1][2]
Regimen
BBleomycin
ADoxorubicin (Adriamycin)
CCyclophosphamide
OVincristine (Oncovin)
DDexamethasone
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Gong G, Du J, Dong L, Lei W, Gao X, Fang B; et al. (2014). "[Efficacy of adjusted BACOD regimen on the treatment of relapsed refractory diffuse large B cell lymphoma]". Zhonghua Xue Ye Xue Za Zhi. 35 (4): 295–9. doi:10.3760/cma.j.issn.0253-2727.2014.04.010. PMID 24759015.